Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meptazinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meptazinol SCHEMBL12125416 | 1.00 | ACHE (1.00) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL11947491 | 1.00 | ACHE (1.00) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL124401 | 0.99 | ACHE (0.97) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL542305 | 0.99 | ACHE (0.97) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL1651915 | 0.97 | ACHE (0.95) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL3375335 | 0.93 | ACHE (0.86) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL542368 | 0.93 | ACHE (0.86) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL999304 | 0.93 | ACHE (0.86) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL4412890 | 0.91 | ACHE (0.82) | ACHESLC22A1CHRM2SLC6A4OPRM1 | |
| Meptazinol SCHEMBL11481015 | 0.91 | ACHE (0.82) | ACHESLC22A1CHRM2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11084 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12564597-B2 | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE OF NEW YORK (US) | 2026-03-03 | — | — | US | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2025123013-A1 | COMPOSITIONS FOR TREATING ADDICTION, DEPENDENCE, WITHDRAWAL, AND/OR OPIOID INDUCED HYPERALGESIA | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| US-4466963-A | ANALGESICS CONTAINING IBUPROFEN AND MEPTAZINOL | JOHN WYETH & BROTHER LIMITED (GB) | 1984-08-21 | — | — | US | claimed |
| US-4464376-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | RICHARDSON-VICKS, INC. (US) | 1984-08-07 | — | — | US | claimed |
| EP-0099186-A2 | Pharmaceutical compositions | JOHN WYETH & BROTHER LIMITED (GB) | 1984-01-25 | — | — | EP | claimed |
| US-4399129-A | ADMINISTERING MEPTAZINOL | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-08-16 | — | — | US | claimed |